<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382303</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-CT4-10-055</org_study_id>
    <nct_id>NCT01382303</nct_id>
  </id_info>
  <brief_title>Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients</brief_title>
  <official_title>Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients : Prospective, Randomized, Double Blinded Active Control, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized controlled study aims to evaluate the effects of pentoxifylline
      on proteinuria in Korean type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit adults patients with type 2 diabetes aged over 20 years with
      spot urine albumin to creatinine ratio over 30mg/g in two consecutive measurements.

      Enrolled patients will be randomly assigned to receive pentoxifylline (400mg three times
      daily) or placebo for 24 weeks.

      Fasting blood and spot urine will be collected at baseline, 12 weeks and 24 weeks.

      The investigators will evaluate the impact of pentoxifylline on proteinuria in type 2
      diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2010</start_date>
  <completion_date type="Actual">December 20, 2013</completion_date>
  <primary_completion_date type="Actual">December 20, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Proteinuia</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Changes of urine protein to creatinie ratio from baseline to 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Albuminuria</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Changes of urine albumin to creatinie ratio from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of eGFR</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>changes in eGFR from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of Creatinine</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>changes serum creatinine from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of Fasting Glucose</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>changes serum fasting glucose from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of TNF-a</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>changes in TNF-a from baseline to 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentoxifylline 400mg three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>Pentoxifylline 400mg three times a day</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <other_name>Trental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet three times a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  age &gt;=20 years

          -  spot urine albumin/creatinine ratio &gt; 30mg/g in two consecutive measurements

          -  patients on ACE-inhibitor or ARB as an anti-hypertensive drug

          -  blood pressure &lt;= 150/100 mmHg

          -  HbA1c &lt;10%

        Exclusion Criteria:

          -  taking insulin pentoxifylline, cilostazol, ketas, viagra in 3 months

          -  ischemic heart disease, stroke, malignant disease, severe infection in 6 months

          -  serum creatinine &gt; 2.0mg/dl

          -  severe liver disease or AST, ALT &gt; 3* ULM

          -  taking systemic steroid in 1 month

          -  pregnant or plan to become pregnant during the clinical trial

          -  lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwan-Woo Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>February 13, 2017</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2017</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kwan Woo Lee</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>pentoxifylline</keyword>
  <keyword>proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo tablet
Placebo: placebo tablet three times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo tablet
Placebo: placebo tablet three times a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="10.1"/>
                    <measurement group_id="B2" value="63.8" spread="9.4"/>
                    <measurement group_id="B3" value="63.8" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Proteinuia</title>
        <description>Changes of urine protein to creatinie ratio from baseline to 24 weeks</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet
Placebo: placebo tablet three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Proteinuia</title>
          <description>Changes of urine protein to creatinie ratio from baseline to 24 weeks</description>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23" lower_limit="-50" upper_limit="10"/>
                    <measurement group_id="O2" value="-4" lower_limit="-30" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Albuminuria</title>
        <description>Changes of urine albumin to creatinie ratio from baseline to 24 weeks</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet
Placebo: placebo tablet three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Albuminuria</title>
          <description>Changes of urine albumin to creatinie ratio from baseline to 24 weeks</description>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-47" upper_limit="50"/>
                    <measurement group_id="O2" value="-6" lower_limit="-45" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of eGFR</title>
        <description>changes in eGFR from baseline to 24 weeks</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet
Placebo: placebo tablet three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of eGFR</title>
          <description>changes in eGFR from baseline to 24 weeks</description>
          <units>ml/min per 1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="18.20"/>
                    <measurement group_id="O2" value="-3.59" spread="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of Creatinine</title>
        <description>changes serum creatinine from baseline to 24 weeks</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet
Placebo: placebo tablet three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of Creatinine</title>
          <description>changes serum creatinine from baseline to 24 weeks</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.16"/>
                    <measurement group_id="O2" value="0.04" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of Fasting Glucose</title>
        <description>changes serum fasting glucose from baseline to 24 weeks</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet
Placebo: placebo tablet three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of Fasting Glucose</title>
          <description>changes serum fasting glucose from baseline to 24 weeks</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="38.9"/>
                    <measurement group_id="O2" value="8.4" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of TNF-a</title>
        <description>changes in TNF-a from baseline to 24 weeks</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo tablet
Placebo: placebo tablet three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of TNF-a</title>
          <description>changes in TNF-a from baseline to 24 weeks</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="3.11"/>
                    <measurement group_id="O2" value="0.14" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline 400mg three times a day
Pentoxifylline: Pentoxifylline 400mg three times a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo tablet
Placebo: placebo tablet three times a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>nasea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>gastric reflux</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kwan Woo Lee</name_or_title>
      <organization>Ajou University</organization>
      <phone>82-31-219-4526</phone>
      <email>LKW65@ajou.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

